{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:50:42Z","timestamp":1793573442083,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["U01 CA137088"],"award-info":[{"award-number":["U01 CA137088"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA201407"],"award-info":[{"award-number":["R01 CA201407"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA273198"],"award-info":[{"award-number":["R01 CA273198"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00125-025-06631-z","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:13:45Z","timestamp":1765833225000},"page":"942-952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diabetogenic processes for insulin resistance-linked hyperinsulinaemia are associated with colorectal cancer"],"prefix":"10.1007","volume":"69","author":[{"given":"Xuan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6135-9998","authenticated-orcid":false,"given":"Magdalena","family":"Sevilla-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-9623","authenticated-orcid":false,"given":"Amanda I.","family":"Phipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-9162","authenticated-orcid":false,"given":"Miriam","family":"Udler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-5097","authenticated-orcid":false,"given":"Sergi","family":"Castellv\u00ed-Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-6767","authenticated-orcid":false,"given":"Andrew T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0127-9790","authenticated-orcid":false,"given":"Andrew J.","family":"Pellatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7153-2766","authenticated-orcid":false,"given":"Robert E.","family":"Schoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Giovannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5472-6761","authenticated-orcid":false,"given":"Marc J.","family":"Gunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-9325","authenticated-orcid":false,"given":"Jose C.","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5666-9318","authenticated-orcid":false,"given":"Ulrike","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-1438","authenticated-orcid":false,"given":"Jordi","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"10397","key":"6631_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, Stafford LK, McLaughlin SA et al (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402(10397):203\u2013234. https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6","journal-title":"Lancet"},{"issue":"3","key":"6631_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2337\/dc14-1175","volume":"38","author":"PJHL Peeters","year":"2015","unstructured":"Peeters PJHL, Bazelier MT, Leufkens HGM, De Vries F, De Bruin ML (2015) The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. Diabetes Care 38(3):405\u2013502. https:\/\/doi.org\/10.2337\/dc14-1175","journal-title":"Diabetes Care"},{"issue":"19","key":"6631_CR3","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.3748\/wjg.v21.i19.6026","volume":"21","author":"SY Guraya","year":"2015","unstructured":"Guraya SY (2015) Association of type 2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review. World J Gastroenterol 21(19):6026\u20136031. https:\/\/doi.org\/10.3748\/wjg.v21.i19.6026","journal-title":"World J Gastroenterol"},{"issue":"10207","key":"6631_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394(10207):1467\u20131480. https:\/\/doi.org\/10.1016\/S0140-6736(19)32319-0","journal-title":"Lancet"},{"issue":"11","key":"6631_CR5","doi-asserted-by":"publisher","first-page":"e2343333","DOI":"10.1001\/jamanetworkopen.2023.43333","volume":"6","author":"T Lawler","year":"2023","unstructured":"Lawler T, Walts ZL, Steinwandel M et al (2023) Type 2 diabetes and colorectal cancer risk. JAMA Netw Open 6(11):e2343333. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.43333","journal-title":"JAMA Netw Open"},{"issue":"5","key":"6631_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/J.CCELL.2025.03.033","volume":"43","author":"SM Samuel","year":"2025","unstructured":"Samuel SM, Varghese E, B\u00fcsselberg D (2025) Complexity of insulin resistance in early-onset colorectal cancer. Cancer Cell 43(5):797\u2013802. https:\/\/doi.org\/10.1016\/J.CCELL.2025.03.033","journal-title":"Cancer Cell"},{"issue":"11","key":"6631_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-020-0295-5","volume":"20","author":"EJ Gallagher","year":"2020","unstructured":"Gallagher EJ, LeRoith D (2020) Hyperinsulinaemia in cancer. Nat Rev Cancer 20(11):629\u2013644. https:\/\/doi.org\/10.1038\/s41568-020-0295-5","journal-title":"Nat Rev Cancer"},{"issue":"9922","key":"6631_CR8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","volume":"383","author":"T Tuomi","year":"2014","unstructured":"Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L (2014) The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383(9922):1084\u20131094. https:\/\/doi.org\/10.1016\/S0140-6736(13)62219-9","journal-title":"Lancet"},{"issue":"5","key":"6631_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00125-017-4210-x","volume":"60","author":"MI McCarthy","year":"2017","unstructured":"McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes. Diabetologia 60(5):793\u2013799. https:\/\/doi.org\/10.1007\/s00125-017-4210-x","journal-title":"Diabetologia"},{"issue":"5","key":"6631_CR10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/jnci\/djac011","volume":"114","author":"N Murphy","year":"2022","unstructured":"Murphy N, Song M, Papadimitriou N et al (2022) Associations between glycemic traits and colorectal cancer: a Mendelian randomization analysis. J Natl Cancer Inst 114(5):740\u2013752. https:\/\/doi.org\/10.1093\/jnci\/djac011","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"6631_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4239\/wjd.v11.i6.227","volume":"11","author":"M Wang","year":"2020","unstructured":"Wang M, Yang Y, Liao Z (2020) Diabetes and cancer: epidemiological and biological links. World J Diabetes 11(6):227\u2013238. https:\/\/doi.org\/10.4239\/wjd.v11.i6.227","journal-title":"World J Diabetes"},{"issue":"1","key":"6631_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01073-0","volume":"7","author":"M Li","year":"2022","unstructured":"Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H (2022) Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther 7(1):1\u201325. https:\/\/doi.org\/10.1038\/s41392-022-01073-0","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"6631_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cmet.2019.07.003","volume":"30","author":"AMY Zhang","year":"2019","unstructured":"Zhang AMY, Magrill J, de Winter TJJ et al (2019) Endogenous hyperinsulinemia contributes to pancreatic cancer development. Cell Metab 30(3):403\u2013404. https:\/\/doi.org\/10.1016\/j.cmet.2019.07.003","journal-title":"Cell Metab"},{"issue":"1","key":"6631_CR14","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1038\/S41467-025-57452-Y","volume":"16","author":"M Sevilla-Gonz\u00e1lez","year":"2025","unstructured":"Sevilla-Gonz\u00e1lez M, Smith K, Wang N et al (2025) Heterogeneous effects of genetic variants and traits associated with fasting insulin on cardiometabolic outcomes. Nat Commun 16(1):2569. https:\/\/doi.org\/10.1038\/S41467-025-57452-Y","journal-title":"Nat Commun"},{"issue":"10","key":"6631_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jech-2018-210651","volume":"72","author":"Y Pang","year":"2018","unstructured":"Pang Y, Kartsonaki C, Guo Y et al (2018) Diabetes, plasma glucose and incidence of colorectal cancer in Chinese adults: a prospective study of 0.5 million people. J Epidemiol Community Health 72(10):919\u2013925. https:\/\/doi.org\/10.1136\/jech-2018-210651","journal-title":"J Epidemiol Community Health"},{"issue":"11","key":"6631_CR16","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2337\/DC23-1013","volume":"46","author":"F Zaccardi","year":"2023","unstructured":"Zaccardi F, Ling S, Brown K, Davies M, Khunti K (2023) Duration of type 2 diabetes and incidence of cancer: an observational study in England. Diabetes Care 46(11):1923\u20131930. https:\/\/doi.org\/10.2337\/DC23-1013","journal-title":"Diabetes Care"},{"issue":"6","key":"6631_CR17","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/er.2019-00088","volume":"40","author":"MS Udler","year":"2019","unstructured":"Udler MS, McCarthy MI, Florez JC, Mahajan A (2019) Genetic risk scores for diabetes diagnosis and precision medicine. Endocr Rev 40(6):1500\u20131520. https:\/\/doi.org\/10.1210\/er.2019-00088","journal-title":"Endocr Rev"},{"issue":"8003","key":"6631_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41586-024-07019-6","volume":"627","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Hatzikotoulas K, Southam L et al (2024) Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature 627(8003):347\u2013357. https:\/\/doi.org\/10.1038\/s41586-024-07019-6","journal-title":"Nature"},{"issue":"9","key":"6631_CR19","doi-asserted-by":"publisher","first-page":"e1002654","DOI":"10.1371\/journal.pmed.1002654","volume":"15","author":"MS Udler","year":"2018","unstructured":"Udler MS, Kim J, von Grotthuss M et al (2018) Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med 15(9):e1002654. https:\/\/doi.org\/10.1371\/journal.pmed.1002654","journal-title":"PLoS Med"},{"issue":"3","key":"6631_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2337\/dc21-1395","volume":"45","author":"D Dicorpo","year":"2022","unstructured":"Dicorpo D, Leclair J, Cole JB et al (2022) Type 2 diabetes partitioned polygenic scores associate with disease outcomes in 454,193 individuals across 13 cohorts. Diabetes Care 45(3):674\u2013683. https:\/\/doi.org\/10.2337\/dc21-1395","journal-title":"Diabetes Care"},{"issue":"1","key":"6631_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41588-022-01222-9","volume":"55","author":"C Fernandez-Rozadilla","year":"2022","unstructured":"Fernandez-Rozadilla C, Timofeeva M, Chen Z et al (2022) Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet 55(1):89\u201399. https:\/\/doi.org\/10.1038\/s41588-022-01222-9","journal-title":"Nat Genet"},{"key":"6631_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015) Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4:7. https:\/\/doi.org\/10.1186\/s13742-015-0047-8","journal-title":"Gigascience"},{"key":"6631_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB (1987) Multiple imputation for nonresponse in surveys. Wiley, New York"},{"issue":"11","key":"6631_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/S41416-018-0314-4","volume":"119","author":"Y Ma","year":"2018","unstructured":"Ma Y, Yang W, Song M et al (2018) Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts. Br J Cancer 119(11):1436\u20131442. https:\/\/doi.org\/10.1038\/S41416-018-0314-4","journal-title":"Br J Cancer"},{"issue":"5","key":"6631_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41591-022-01790-7","volume":"28","author":"ATN Nair","year":"2022","unstructured":"Nair ATN, Wesolowska-Andersen A, Brorsson C et al (2022) Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nat Med 28(5):982\u2013988. https:\/\/doi.org\/10.1038\/s41591-022-01790-7","journal-title":"Nat Med"},{"issue":"2","key":"6631_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-8587(23)00329-7","volume":"12","author":"M Sch\u00f6n","year":"2024","unstructured":"Sch\u00f6n M, Prystupa K, Mori T et al (2024) Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort. Lancet Diabetes Endocrinol 12(2):119\u2013131. https:\/\/doi.org\/10.1016\/S2213-8587(23)00329-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6631_CR27","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/IJC.23606","volume":"123","author":"KK Tsilidis","year":"2008","unstructured":"Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA (2008) C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123(5):1133\u20131140. https:\/\/doi.org\/10.1002\/IJC.23606","journal-title":"Int J Cancer"},{"issue":"4","key":"6631_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/S41571-020-00445-1","volume":"18","author":"N Akimoto","year":"2021","unstructured":"Akimoto N, Ugai T, Zhong R et al (2021) Rising incidence of early-onset colorectal cancer \u2013 a call to action. Nat Rev Clin Oncol 18(4):230\u2013243. https:\/\/doi.org\/10.1038\/S41571-020-00445-1","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"6631_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/J.ANNONC.2024.02.008","volume":"35","author":"RS Laskar","year":"2024","unstructured":"Laskar RS, Qu C, Huyghe JR et al (2024) Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer. Ann Oncol 35(6):523. https:\/\/doi.org\/10.1016\/J.ANNONC.2024.02.008","journal-title":"Ann Oncol"},{"issue":"4","key":"6631_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.14309\/AJG.0000000000002171","volume":"118","author":"T Ugai","year":"2022","unstructured":"Ugai T, Haruki K, Harrison TA et al (2022) Molecular characteristics of early-onset colorectal cancer according to detailed anatomical locations: comparison to later-onset cases. Am J Gastroenterol 118(4):712. https:\/\/doi.org\/10.14309\/AJG.0000000000002171","journal-title":"Am J Gastroenterol"},{"issue":"14","key":"6631_CR31","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMOA2407934","volume":"392","author":"JK McHugh","year":"2025","unstructured":"McHugh JK, Bancroft EK, Saunders E et al (2025) Assessment of a polygenic risk score in screening for prostate cancer. N Engl J Med 392(14):1406\u20131417. https:\/\/doi.org\/10.1056\/NEJMOA2407934","journal-title":"N Engl J Med"},{"issue":"3","key":"6631_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cgh.2022.12.006","volume":"21","author":"GM Cavestro","year":"2023","unstructured":"Cavestro GM, Mannucci A, Balaguer F et al (2023) Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) international management guidelines. Clin Gastroenterol Hepatol 21(3):581-603.e33. https:\/\/doi.org\/10.1016\/j.cgh.2022.12.006","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06631-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:51:55Z","timestamp":1772553115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06631-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["6631"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06631-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The CCFR graciously acknowledges the generous contributions of the study participants, the dedication of study staff and the financial support from the US National Cancer Institute, without which this important registry would not exist. The authors would like to thank the study participants and staff of the Seattle Colon Cancer Family Registry and the Hormones and Colon Cancer study (CORE Studies). Acknowledgements pertaining to the specific studies included are provided in the\n                      \n                      (Funding support and acknowledgements from participating studies).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The data underlying the generation of the global polygenic score for type 2 diabetes are available from Suzuki et\u00a0al [\n                      \n                      ]. Information including the procedures to obtain and access the data and codes used in this study in the GECCO and CCFR consortia is described at\n                      \n                      . The scripts used to analyse GECCO and CCFR data presented in this manuscript are available upon request by contacting the corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"GECCO is supported by the National Cancer Institute (NCI), National Institutes of Health (NIH), US Department of Health and Human Services (U01 CA137088, R01 CA201407, R01 CA273198). Genotyping\/sequencing services were provided by the Center for Inherited Disease Research (CIDR) under contract numbers HHSN268201700006I and HHSN268201200008I. This research was funded in part through NIH\/NCI Cancer Center support grant P30 CA015704. The Scientific Computing Infrastructure at Fred Hutchinson Cancer Center is funded by ORIP grant S10OD028685. This work was delivered as part of the Team PROSPECT (ATC), supported by the Cancer Grand Challenges partnership funded by Cancer Research UK (CGCATF-2023\/100036), the NCI (OT2CA297680), the Bowelbabe Fund for Cancer Research UK and the Institut National du Cancer. CCFR is supported in part by funding from the NCI\/NIH (award U01 CA167551). Support for case ascertainment was provided in part by the Surveillance, Epidemiology and End Results (SEER) Program, US state cancer registries in Arizona, Colorado, Minnesota, North Carolina and New Hampshire, and the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada). The CCFR Set-1 (Illumina 1M\/1M-Duo) and Set-2 (Illumina Omni1-Quad) scans were supported by NIH awards U01 CA122839 and R01 CA143237. The CCFR Set-3 (Affymetrix Axiom CORECT Set array) scan was supported by NIH awards U19 CA148107 and R01 CA81488. The CCFR Set-4 (Illumina OncoArray 600K SNP array) scan was supported by NIH award U19 CA148107 and by the CIDR, which is funded by a grant from the NIH to Johns Hopkins University (contract number HHSN268201200008I). Additional funding for the OFCCR was provided through award GL201-043 from the Ontario Research Fund, award 112746 from the Canadian Institutes of Health Research, a Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society, and through generous support from the Ontario Ministry of Research and Innovation. Additional support for the CCFR was in part through NCI\/NIH awards U01\/U24 CA074794 and R01 CA076366. The content of this manuscript does not necessarily reflect the views or policies of the NCI, NIH or any of the collaborating centres in the CCFR, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government, any cancer registry or the CCFR. JM was supported by Novo Nordisk Foundation grant NNF23SA0084103, an EFSD\/Novo Nordisk Foundation Future Leaders Award (number 0094134) and the European Union (HORIZON-EIC-2023-PATHFINDERCHALLENGES-01-101161509). However, the views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SME Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for these views. ATC is supported by NCI grant R01 R35CA253178 and an American Cancer Society Professorship. MS-G is supported by grants NIDDK UM1 DK078616 and 1K99DK139461-01A1. EG is funded as an American Cancer Society Clinical Research Professor (CRP-23-1014041). Further information on funding is provided in the\n                      \n                      (Funding support and acknowledgements from participating studies).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JM is an Associate Editor for\n                      Diabetologia\n                      but played no role in the evaluation of this manuscript. UP was a consultant with AbbVie and her family hold individual stocks for the following companies: Amazon, Boeing Company, BioNTech, BYD Company Limited, Crowdstrike Holdings Inc., CureVac, Google\/Alphabet, Microsoft Corp, MicroStrategy Inc., NVIDIA Corp and Stellantis. The remaining authors declare that there are no other relationships or activities that might bias, or be perceived to bias, this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"The study was conceptualised by MS, JM and EG. XZ validated and verified the data. The methodology was developed by JM, MS-G, UP, AIP and MS. JM wrote the original draft and visualised the findings; the draft was reviewed and edited by MS-G, XZ and MS. All authors contributed to the interpretation of data, reviewed the manuscript, and agreed to the final version of the manuscript. JM is the guarantor of this work, and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}